153sm-dotmp
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03612466)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07197645 | Phase 1 | Oct 15, 2025 | Telix |
| NCT06008483 | Phase 1 | Apr 5, 2022 | QSAM Therapeutics, Inc. |
| NCT03612466 | Phase 1 | Sep 30, 2018 | Yeshiva University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| QSAM Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Telix | For profit | 1 | 1 | 1 | 2025 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1